MBIO Stock Overview
Operates as a clinical stage drug development company in Australasia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MindBio Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.085 |
| 52 Week Low | CA$0.015 |
| Beta | 0 |
| 11 Month Change | -16.67% |
| 3 Month Change | 0% |
| 1 Year Change | 25.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| MBIO | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 25.0% | -6.9% | 2.2% |
| 1Y | 25.0% | -22.8% | 23.4% |
Return vs Industry: MBIO exceeded the Canadian Pharmaceuticals industry which returned -23.2% over the past year.
Return vs Market: MBIO exceeded the Canadian Market which returned 23.4% over the past year.
Price Volatility
| MBIO volatility | |
|---|---|
| MBIO Average Weekly Movement | 28.0% |
| Pharmaceuticals Industry Average Movement | 12.0% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MBIO's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: MBIO's weekly volatility has decreased from 34% to 28% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Justin Hanka | www.mindbiotherapeutics.com |
MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions. It also establishes and executes research protocols through formal clinical trials that are facilitated via digital therapeutic platforms; and invests in research for developing treatments for depression, anxiety, PTSD and chronic pain.
MindBio Therapeutics Corp. Fundamentals Summary
| MBIO fundamental statistics | |
|---|---|
| Market cap | CA$3.38m |
| Earnings (TTM) | -CA$248.60k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.6x
P/E RatioIs MBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBIO income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$0 |
| Other Expenses | AU$273.69k |
| Earnings | -AU$273.69k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.002 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -84.8% |
How did MBIO perform over the long term?
See historical performance and comparison